Hypertriglyceridemia

20
Pipeline Programs
9
Companies
20
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
7
0
6
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
343%
Small Molecule
229%
Peptide
114%
Monoclonal Antibody
114%
+ 13 programs with unclassified modality

On Market (1)

Approved therapies currently available

AstraZeneca
CRESTORApproved
rosuvastatin
AstraZeneca
oral2003

Competitive Landscape

8 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
1
2
1
rosuvastatinPhase 4Small Molecule1 trial
EpanovaPhase 31 trial
Olive oil, 4gPhase 31 trial
SimvastatinPhase 1Small Molecule1 trial
Active Trials
NCT01486433Completed52Est. Mar 2012
NCT02009865Completed379Est. Dec 2014
NCT01408303Completed646Est. Jun 2012
+1 more trials
Ionis Pharmaceuticals
6 programs
1
3
2
OlezarsenPhase 3RNA Therapeutic1 trial
VolanesorsenPhase 3RNA Therapeutic1 trial
ISIS 678354Phase 21 trial
ISIS apoC-III RxPhase 21 trial
OlezarsenPhase 2RNA Therapeutic1 trial
+1 more programs
Active Trials
NCT02709850Completed48Est. Jun 2017
NCT03385239Completed114Est. Feb 2020
NCT01529424Completed89Est. Jan 2014
+3 more trials
Arrowhead Pharmaceuticals
3 programs
1
2
Plozasiran InjectionPhase 31 trial
Plozasiran InjectionPhase 31 trial
ARO-APOC3Phase 11 trial
Active Trials
NCT03783377Completed112Est. Feb 2021
NCT06822790Recruiting869Est. Jul 2028
NCT06347133Active Not Recruiting1,456Est. Sep 2026
Marea Therapeutics
Marea TherapeuticsCA - South SF
3 programs
1
2
MAR001Phase 21 trial
MAR001Phase 21 trial
MAR001Phase 1/21 trial
Active Trials
NCT05896254CompletedEst. Dec 2024
NCT07028749Active Not RecruitingEst. Dec 2026
NCT07199309RecruitingEst. Nov 2026
Rhythm Pharmaceuticals
1 program
1
SetmelanotidePhase 2Peptide1 trial
Active Trials
NCT03262610Completed1Est. Jan 2018
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
evinacumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT04863014Terminated21Est. Feb 2023
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
LY3875383Phase 11 trial
Active Trials
NCT05609825Terminated41Est. Jan 2024
Abbott
AbbottABBOTT PARK, IL
1 program
TricorN/A1 trial
Active Trials
NCT04650152Completed1,000Est. Nov 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecarosuvastatin
Arrowhead PharmaceuticalsPlozasiran Injection
Arrowhead PharmaceuticalsPlozasiran Injection
Ionis PharmaceuticalsOlezarsen
Ionis PharmaceuticalsVolanesorsen
AstraZenecaEpanova
AstraZenecaOlive oil, 4g
Marea TherapeuticsMAR001
Marea TherapeuticsMAR001
Ionis PharmaceuticalsOlezarsen
Regeneronevinacumab
Ionis PharmaceuticalsISIS 678354
Rhythm PharmaceuticalsSetmelanotide
Ionis PharmaceuticalsISIS apoC-III Rx
Marea TherapeuticsMAR001

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 6,908 patients across 20 trials

NCT00473655AstraZenecarosuvastatin

Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients

Start: Jan 2007Est. completion: Feb 2009334 patients
Phase 4Completed
NCT06822790Arrowhead PharmaceuticalsPlozasiran Injection

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Start: Apr 2025Est. completion: Jul 2028869 patients
Phase 3Recruiting
NCT06347133Arrowhead PharmaceuticalsPlozasiran Injection

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Start: May 2024Est. completion: Sep 20261,456 patients
Phase 3Active Not Recruiting
NCT05610280Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Start: Nov 2022Est. completion: Jun 20251,478 patients
Phase 3Completed
NCT02300233Ionis PharmaceuticalsVolanesorsen

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Start: Feb 2015Est. completion: Jan 2017114 patients
Phase 3Completed
NCT02009865AstraZenecaEpanova

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Start: Dec 2013Est. completion: Dec 2014379 patients
Phase 3Completed
NCT01408303AstraZenecaOlive oil, 4g

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

Start: Aug 2011Est. completion: Jun 2012646 patients
Phase 3Completed
NCT07199309Marea TherapeuticsMAR001

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Start: Sep 2025Est. completion: Nov 2026
Phase 2Recruiting
NCT07028749Marea TherapeuticsMAR001

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Start: Jun 2025Est. completion: Dec 2026
Phase 2Active Not Recruiting
NCT05355402Ionis PharmaceuticalsOlezarsen

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Start: May 2022Est. completion: Dec 2023154 patients
Phase 2Completed
NCT04863014Regeneronevinacumab

Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Start: Jul 2021Est. completion: Feb 202321 patients
Phase 2Terminated
NCT03385239Ionis PharmaceuticalsISIS 678354

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

Start: Jan 2018Est. completion: Feb 2020114 patients
Phase 2Completed
NCT03262610Rhythm PharmaceuticalsSetmelanotide

Setmelanotide in a Single Patient With Partial Lipodystrophy

Start: Aug 2017Est. completion: Jan 20181 patients
Phase 2Completed
NCT01529424Ionis PharmaceuticalsISIS apoC-III Rx

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Start: Feb 2012Est. completion: Jan 201489 patients
Phase 2Completed
NCT05896254Marea TherapeuticsMAR001

Study of MAR001 in Adults With Metabolic Dysfunction

Start: Jul 2023Est. completion: Dec 2024
Phase 1/2Completed
NCT05609825Eli Lilly and CompanyLY3875383

A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia

Start: Nov 2022Est. completion: Jan 202441 patients
Phase 1Terminated
NCT03783377Arrowhead PharmaceuticalsARO-APOC3

Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Start: Mar 2019Est. completion: Feb 2021112 patients
Phase 1Completed
NCT02709850Ionis PharmaceuticalsIONIS ANGPTL3-LRx

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia

Start: Nov 2015Est. completion: Jun 201748 patients
Phase 1Completed
NCT01486433AstraZenecaSimvastatin

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

Start: Nov 2011Est. completion: Mar 201252 patients
Phase 1Completed
NCT04650152AbbottTricor

Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)

Start: Oct 2020Est. completion: Nov 20211,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 6,908 patients
9 companies competing in this space